Drug profile · INN
tirzepatide
MOUNJARO
- US status
- approved
- Patents linked
- 0
- News articles
- 2
Quick answer
tirzepatide (MOUNJARO) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Related news
Novo Nordisk Reports Record Q1 Revenue Driven by Wegovy and Ozempic Demand
Novo Nordisk has reported record Q1 revenue driven by strong demand for Wegovy and Ozempic. This article analyzes the implications for investors and the competitive landscape.
FDA Approves Mounjaro: Key Details on Tirzepatide for Obesity
The FDA has officially approved Mounjaro, a new medication containing tirzepatide, for the treatment of obesity, offering hope for effective weight management.
Frequently asked questions
What is tirzepatide?
tirzepatide (MOUNJARO) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for tirzepatide?
MOUNJARO is a marketed brand name for tirzepatide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tirzepatide?
tirzepatide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.